highly significantp = 0.003
The estimated pooled OR for both 2 trials shows a highly significant reduction of the risk of recurrence for patients receiving adoptive immunotherapy (OR = 0.35; 95% CI, 0.17 to 0.71; p = 0.003; Fig. 2 ).
The estimated pooled OR for both 2 trials shows a highly significant reduction of the risk of recurrence for patients receiving adoptive immunotherapy (OR = 0.35; 95% CI, 0.17 to 0.71; p = 0.003; Fig. 2 ).